Congress trades
Integra LifeSciences Holdings Corporation (IART)
Free on iOS and Android.
About Integra LifeSciences Holdings Corporation
from the company's filings and listing, as of Oct 26, 2026- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Devices
- Chief executive
- Stuart Essig
- Employees
- 4,427
- Listed since
- Aug 16, 1995
- Market value
- $926.3M
- Price to earnings (12 mo)
- 71.0
- Net income per share, as reported (12 mo)
- $0.17
- Dividend yield
- -
Earnings
6 reported quarters · next on Feb 25, 2027| Quarter | EPS | EPS expected | Revenue | Revenue expected | Result |
|---|---|---|---|---|---|
| Q3 FY2026reported Oct 21, 2026 | $0.59 | $0.56 | $411.2M | $413.2M | EPS beatRevenue in line |
| Q2 FY2026reported Jul 29, 2026 | $0.56 | $0.48 | $418.8M | $417.5M | EPS beatRevenue in line |
| Q1 FY2026reported May 5, 2026 | $0.54 | $0.41 | $391.9M | $381.8M | EPS beatRevenue beat |
| Q4 FY2025reported Feb 26, 2026 | $0.83 | $0.79 | $434.9M | $429.6M | EPS beatRevenue in line |
| Q3 FY2025reported Oct 30, 2025 | $0.54 | $0.43 | $402.1M | $429.6M | EPS beatRevenue miss |
| Q2 FY2025reported Jul 31, 2025 | $0.45 | $0.43 | $415.6M | $414.3M | EPS beatRevenue in line |
Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.
Executive pay
as filed for fiscal 2025 · proxy filed Apr 6, 2026| Executive | Salary | Stock awards | Other | Total |
|---|---|---|---|---|
| Mojdeh PoulPresident and Chief Executive Officer and Director | $1.0M | $5.2M | $3.1M | $9.4M |
| Lea KnightExecutive Vice President and Chief Financial Officer | $639K | $1.5M | $746K | $2.9M |
| Michael J. McBreenExecutive Vice President, President, Codman Specialty Surgical | $644K | $1.3M | $742K | $2.7M |
| Robert T. Davis, JrExecutive Vice President, President, Tissue Technologies | $583K | $893K | $437K | $1.9M |
| Harvinder SinghExecutive Vice President, President, International | $564K | $683K | $378K | $1.6M |
The summary compensation table from the proxy statement for fiscal 2025, with titles as filed then. 1 executive who has since left the company is named in that filing and not shown here. Read the filing
Institutional holders
13F positions as of Jun 30, 2026| Holder | Value | Shares | Shares vs prior qtr | % of shares out |
|---|---|---|---|---|
| BlackRock, Inc. | $191.9M | 10,684,103 | +3.5% | 13.67% |
| Rubric Capital Management LP | $139.3M | 7,753,934 | 0.0% | 9.92% |
| Invesco Ltd. | $67.3M | 3,749,367 | +7.6% | 4.80% |
| Vanguard Portfolio Management LLC | $67.2M | 3,743,093 | +1.5% | 4.79% |
| Morgan Stanley | $64.5M | 3,593,079 | +0.2% | 4.60% |
| Paradigm Capital Management Inc | $61.8M | 3,439,098 | -14.3% | 4.40% |
| Fuller & Thaler Asset Management, Inc. | $61.7M | 3,436,006 | -2.6% | 4.40% |
| State Street Corp | $52.9M | 2,946,862 | +2.1% | 3.77% |
| Vanguard Capital Management LLC | $52.9M | 2,946,173 | +1.9% | 3.77% |
| Neuberger Berman Group LLC | $42.6M | 2,364,777 | +11.8% | 3.03% |
| Dimensional Fund Advisors LP | $39.8M | 2,216,653 | -20.1% | 2.84% |
| Geode Capital Management, LLC | $32.2M | 1,791,635 | +8.1% | 2.29% |
A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.
GetSignal watches Form 4 and STOCK Act filings and pushes each one to your phone as it is published, with the history behind it. Free on iOS and Android.
Congress trades in IART
12 disclosures of 12 on record · median 29d of the 45 allowedSince the trade: the stock's move from the trade date to the latest close we hold (figures as of Oct 24, 2026), not the member's result. Not investment advice.
| Member | Type | Action | Amount disclosed | Stock since the trade | Trade date | Disclosed | Delay |
|---|---|---|---|---|---|---|---|
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -58.9%After the saleS&P 500 +38.5% · -97.5 pts vs S&P 500 | Jun 18, 2024 | Jul 9, 2024 | 21d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -65.0%After the saleS&P 500 +46.6% · -111.6 pts vs S&P 500 | Apr 5, 2024 | May 15, 2024 | 40d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -69.0%S&P 500 +74.4% · -143.4 pts vs S&P 500 | Oct 16, 2023 | Nov 11, 2023 | 26d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -69.9%After the saleS&P 500 +70.9% · -140.9 pts vs S&P 500 | Sep 15, 2023 | Oct 15, 2023 | 30d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -71.1%After the saleS&P 500 +74.1% · -145.2 pts vs S&P 500 | Jun 13, 2023 | Jul 11, 2023 | 28d |
| Ro Khanna | Stock | Purchase | $1,001 - $15,000 | -83.5%S&P 500 +62.2% · -145.7 pts vs S&P 500 | Nov 5, 2021 | Dec 7, 2021 | 32d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -75.4%S&P 500 +119.0% · -194.4 pts vs S&P 500 | Oct 16, 2020 | Nov 5, 2020 | 20d |
| Josh GottheimerJoint | Stock | Sale | $1,001 - $15,000 | -73.8%After the saleS&P 500 +123.5% · -197.3 pts vs S&P 500 | Sep 15, 2020 | Oct 13, 2020 | 28d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -75.8%S&P 500 +164.8% · -240.6 pts vs S&P 500 | Mar 10, 2020 | Apr 16, 2020 | 37d |
| Josh GottheimerJoint | Stock | Purchase | $1,001 - $15,000 | -78.5%S&P 500 +134.6% · -213.1 pts vs S&P 500 | Feb 3, 2020 | Mar 16, 2020 | 42d |
| Gilbert Ray Cisneros, Jr. | Stock | Purchase | $1,001 - $15,000 | -79.5%S&P 500 +127.2% · -206.7 pts vs S&P 500 | Feb 10, 2020 | Mar 10, 2020 | 29d |
| Thom TillisJoint | Stock | Sale (Full) | $1,001 - $15,000 | -58.1%After the saleS&P 500 +263.1% · -321.2 pts vs S&P 500 | Feb 13, 2015 | Feb 26, 2015 | 13d |
Since the trade is an estimate, set beside the S&P 500 over the same window, with the gap between the two in percentage points. The filing carries a band, not a fill, and a sale keeps the stock's sign, so a positive figure after a sale means the stock kept rising after it. An option row carries the underlying stock's move. A row marked n/a is one we hold no figure for.
A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.
"Not captured" means the band or the transaction type on the original report is missing from our data.
"Dates conflict" marks a row whose disclosure is dated before its trade on the record we hold. Both dates are printed as filed, and no since-the-trade figure is computed from them.
Every Congress trade in IART, filterable by party, chamber, type and account.
Questions
Which members of Congress have traded IART?
Josh Gottheimer, Ro Khanna, Gilbert Ray Cisneros, Jr. and Thom Tillis disclosed IART transactions in the filings shown here.
How quickly are IART trades disclosed?
Congressional disclosures took a median of 29 days, against the 45 the STOCK Act allows.
How to read a STOCK Act filing
WHAT THE FILING ACTUALLY SAYS
Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.
Data as of Oct 26, 2026.